These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21685036)

  • 1. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.
    Yu J; Dabbs DJ; Shuai Y; Niemeier LA; Bhargava R
    Am J Clin Pathol; 2011 Jul; 136(1):88-97. PubMed ID: 21685036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic subtypes of invasive lobular carcinoma in correlation with tumor status and hormone receptors.
    Mise I; Vucić M; Maricević I; Sokcević M; Curić-Jurić S
    Acta Clin Croat; 2010 Sep; 49(3):275-81. PubMed ID: 21462816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
    Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
    Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
    Turashvili G; Bouchalova K; Bouchal J; Kolar Z
    Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-year survey of classical and pleomorphic invasive lobular breast carcinomas in women from southeastern Serbia: Differences in clinicopathological and immunohistochemical features.
    Ilic IR; Djordjevic NP; Randjelovic PJ; Stojanovic NM; Radulovic NS; Ilic RS
    J BUON; 2016; 21(5):1113-1120. PubMed ID: 27837612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.
    Manucha V; Khilko N; Reilly K; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):200-5. PubMed ID: 21326816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls.
    Varga Z; Mallon E
    Breast Dis; 2008-2009; 30():15-9. PubMed ID: 19850991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast.
    Zhang H; Moisini I; Ajabnoor RM; Turner BM; D'aguiar M; Cai X; Gao S; Yang Q; Wang X; Schiffhauer L; Hicks DG
    Am J Clin Pathol; 2020 Apr; 153(5):583-592. PubMed ID: 31786600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
    Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA
    Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
    Monhollen L; Morrison C; Ademuyiwa FO; Chandrasekhar R; Khoury T
    Histopathology; 2012 Sep; 61(3):365-77. PubMed ID: 22486370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.